Su‐Jen Lin Tsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Su‐Jen Lin Tsai has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Kuo‐Sin Lin
From the Taipei Blood Center, Taiwan Blood Services Foundation; Institute of Biochemistry and Molecular Biology, National Yang Ming University, Taipei, Taiwan; and the Department of Haematology, University of Cambridge, Cambridge, UK
2 shared publicationsLei Li
From the Taipei Blood Center, Taiwan Blood Services Foundation; Institute of Biochemistry and Molecular Biology, National Yang Ming University, Taipei, Taiwan; and the Department of Haematology, University of Cambridge, Cambridge, UK
2 shared publicationsCheng‐Shen Hung
From the Taipei Blood Center, Taiwan Blood Services Foundation; Institute of Biochemistry and Molecular Biology, National Yang Ming University, Taipei, Taiwan; and the Department of Haematology, University of Cambridge, Cambridge, UK
1 shared publicationJean‐Pierre Allain
From the Taipei Blood Center, Taiwan Blood Services Foundation; Institute of Biochemistry and Molecular Biology, National Yang Ming University, Taipei, Taiwan; and the Department of Haematology, University of Cambridge, Cambridge, UK
1 shared publicationKin‐Fu Chak
From the Institute of Biochemistry and Molecular Biology, National Yang Ming University; Taipei Blood Center, Taiwan Blood Services Foundation; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital; and the Taiwan Blood Services Foundation, Taipei, Taiwan
1 shared publicationMeng‐Hua Yang
Taipei Blood Center, Taiwan Blood Services Foundation, Taipei, Taiwan
1 shared publication
Latest Publications
- 28 December 2009
- Published by Wiley in Transfusion
- Vol. 50 (1) , 65-74
The efficacy of individual‐donation and minipool testing to detect low‐level hepatitis B virus DNA in Taiwan
BACKGROUND: Financial constraints are the main concern in implementing nucleic acid testing (NAT) as routine blood screening in Taiwan. The PROCLEIX ULTRIO assay (Ultrio) on the TIGRIS System (Novartis Diagnostics) was evaluated for its operational performance both for individual‐donation testing (IDT) and in minipools of 4 (MP4) to develop a feasible solution.STUDY DESIGN AND METHODS: Analytical sensitivity was determined by testing WHO international standards. We tested 10,290 blood donors, 4210 in IDT and 6080 in MP4. Potential hepatitis B virus (HBV) yield donors (hepatitis B surface antigen [HBsAg] negative/NAT reactive) were evaluated for up to 9 months' follow‐up. Discordant results between the Ultrio assay and the HBsAg tests were further analyzed by HBV antibody serology, alternative NATs, HBV DNA quantification, and sequencing.RESULTS: The 95% limits of detection in IU/mL (95% confidence interval) were as follows: human immunodeficiency virus Type 1 (HIV‐1), 18 (12‐34); hepatitis C virus (HCV), 4.4 (2.8‐8.9); and HBV, 6.3 (4.4‐11). The retest rates were 0.55% for IDT and 0.33% for MP4. No HIV or HCV yield cases were found, while there were 12 potential HBV yield cases, nine from IDT and three from MP4 testing. Eleven of them were successfully genotyped as B2. Ten of them returned for follow‐up and mostly were determined as occult HBV infection (OBI). The IDT yield rate of 9 in 4210 (0.21%) was fourfold greater than the MP4 yield rate of 3 in 6080 (0.05%; p < 0.05).CONCLUSION: The higher yield rate for IDT versus MP4 demonstrates the benefit to implement a more sensitive NAT strategy in regions having significant OBI carriers such as Taiwan.
- 28 December 2009
- Published by Wiley in Transfusion
- Vol. 50 (1) , 65-74
The efficacy of individual‐donation and minipool testing to detect low‐level hepatitis B virus DNA in Taiwan
BACKGROUND: Financial constraints are the main concern in implementing nucleic acid testing (NAT) as routine blood screening in Taiwan. The PROCLEIX ULTRIO assay (Ultrio) on the TIGRIS System (Novartis Diagnostics) was evaluated for its operational performance both for individual‐donation testing (IDT) and in minipools of 4 (MP4) to develop a feasible solution.STUDY DESIGN AND METHODS: Analytical sensitivity was determined by testing WHO international standards. We tested 10,290 blood donors, 4210 in IDT and 6080 in MP4. Potential hepatitis B virus (HBV) yield donors (hepatitis B surface antigen [HBsAg] negative/NAT reactive) were evaluated for up to 9 months' follow‐up. Discordant results between the Ultrio assay and the HBsAg tests were further analyzed by HBV antibody serology, alternative NATs, HBV DNA quantification, and sequencing.RESULTS: The 95% limits of detection in IU/mL (95% confidence interval) were as follows: human immunodeficiency virus Type 1 (HIV‐1), 18 (12‐34); hepatitis C virus (HCV), 4.4 (2.8‐8.9); and HBV, 6.3 (4.4‐11). The retest rates were 0.55% for IDT and 0.33% for MP4. No HIV or HCV yield cases were found, while there were 12 potential HBV yield cases, nine from IDT and three from MP4 testing. Eleven of them were successfully genotyped as B2. Ten of them returned for follow‐up and mostly were determined as occult HBV infection (OBI). The IDT yield rate of 9 in 4210 (0.21%) was fourfold greater than the MP4 yield rate of 3 in 6080 (0.05%; p < 0.05).CONCLUSION: The higher yield rate for IDT versus MP4 demonstrates the benefit to implement a more sensitive NAT strategy in regions having significant OBI carriers such as Taiwan.
- 14 April 2008
- Published by Wiley in Transfusion
- Vol. 48 (6) , 1198-1206
A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus
BACKGROUND: Blood donors in Taiwan currently are screened for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection by immunoassay. The risk of enzyme immunoassay (EIA)‐negative, nucleic acid amplification technology (NAT)‐reactive donations is not well understood. This study aimed to screen for such donors in Taiwan by a multiplex test (cobas TaqScreen, Roche) on a commercially available NAT system (cobas s 201 system, Roche).STUDY DESIGN AND METHODS: NAT was performed on donors without prescreening in pools of six and NAT‐reactive pools were then resolved to the single donation. Individual‐donor NAT–reactive samples were discriminated by a commercially available polymerase chain reaction (PCR)–based diagnostic assay (COBAS AmpliScreen, Roche). Samples with EIA‐ and NAT‐discordant results were investigated with supplemental serologic and confirmatory tests. Each sample taken from follow‐up of HBV NAT yield cases was tested for HBV serologic profile, NAT, and viral load. The sensitivity and performance efficacy were also evaluated.RESULTS: The 95 percent limit of detection (LOD) for HBV, HCV, and HIV were 5.09, 11.83, and 62.53 IU per mL, respectively. Among 10,727 seronegative donations, 12 HBV NAT yield cases (0.11%) and 1 HCV NAT yield case (0.01%) were detected. Follow‐up results for 1 to 8 months showed that the HCV yield case was a window case and all HBV NAT yield cases were occult carriers.CONCLUSION: The use of NAT detected occult HBV and reduced HCV window period. The yield rate, especially occult HBV, was 10‐ to 100‐fold higher than that in developed, HBV nonendemic countries. Therefore, NAT implementation for routine donor screening in a more cost‐effective manner should contribute to safer blood transfusion in Taiwan.
- 14 April 2008
- Published by Wiley in Transfusion
- Vol. 48 (6) , 1198-1206
A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus
BACKGROUND: Blood donors in Taiwan currently are screened for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection by immunoassay. The risk of enzyme immunoassay (EIA)‐negative, nucleic acid amplification technology (NAT)‐reactive donations is not well understood. This study aimed to screen for such donors in Taiwan by a multiplex test (cobas TaqScreen, Roche) on a commercially available NAT system (cobas s 201 system, Roche).STUDY DESIGN AND METHODS: NAT was performed on donors without prescreening in pools of six and NAT‐reactive pools were then resolved to the single donation. Individual‐donor NAT–reactive samples were discriminated by a commercially available polymerase chain reaction (PCR)–based diagnostic assay (COBAS AmpliScreen, Roche). Samples with EIA‐ and NAT‐discordant results were investigated with supplemental serologic and confirmatory tests. Each sample taken from follow‐up of HBV NAT yield cases was tested for HBV serologic profile, NAT, and viral load. The sensitivity and performance efficacy were also evaluated.RESULTS: The 95 percent limit of detection (LOD) for HBV, HCV, and HIV were 5.09, 11.83, and 62.53 IU per mL, respectively. Among 10,727 seronegative donations, 12 HBV NAT yield cases (0.11%) and 1 HCV NAT yield case (0.01%) were detected. Follow‐up results for 1 to 8 months showed that the HCV yield case was a window case and all HBV NAT yield cases were occult carriers.CONCLUSION: The use of NAT detected occult HBV and reduced HCV window period. The yield rate, especially occult HBV, was 10‐ to 100‐fold higher than that in developed, HBV nonendemic countries. Therefore, NAT implementation for routine donor screening in a more cost‐effective manner should contribute to safer blood transfusion in Taiwan.